The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of TP53, RB1, and PTEN mutations on overall survival in metastatic prostate cancer: A multi-center study via the Guardian Research Network.
 
Mohammad Arfat Ganiyani
No Relationships to Disclose
 
Pushan Prabhakar
No Relationships to Disclose
 
Atulya Aman Khosla
No Relationships to Disclose
 
Shreyas S Bellur
No Relationships to Disclose
 
Arjun Pon Avudaiappan
No Relationships to Disclose
 
Liz Bond
No Relationships to Disclose
 
Suresh Marada
No Relationships to Disclose
 
Andrea McCracken
No Relationships to Disclose
 
Charlie Hurmiz
No Relationships to Disclose
 
Bruno R. Bastos
Consulting or Advisory Role - AstraZeneca; AVEO; Bayer; Dendreon; Epizyme; Genzyme; Janssen Oncology; Lilly; Regeneron
Speakers' Bureau - Exelixis; Pfizer/Myovant; Sanofi/Regeneron; Seattle Genetics/Astellas
Research Funding - Actuate Therapeutics (Inst); Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Tempest Therapeutics (Inst); Tolero Pharmaceuticals (Inst); US Oncology (Inst)
 
Rohan Garje
Research Funding - Amgen (Inst); Endocyte/Advanced Accelerator Applications (Inst); Immunomedics (Inst); Pfizer (Inst); xencor (Inst)